Chief Scientific Officer & Chief Operating Officer
Chief Science and Chief Operating Officer (CSO & COO) Birgitte Rønø joined Evaxion in 2017 and was appointed CSO in 2021 before being promoted to the joint role of CSO and COO in 2026. Dr. Rønø has more than 25 years’ experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte Rønø served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with preclinical and biomarker expertise.
